Publication:
Comparative activity of carbapenem testing: the COMPACT study

Simple item page
dc.contributor.authorKORTEN, VOLKAN
dc.contributor.authorsNordmann, Patrice; Picazo, Juan J.; Mutters, Reinier; Korten, Volkan; Quintana, Alvaro; Laeuffer, Joerg M.; Seak, Joyce Chen Hian; Flamm, Robert K.; Morrissey, Ian
dc.date.accessioned2022-03-14T10:17:05Z
dc.date.available2022-03-14T10:17:05Z
dc.date.issued2011-05-01
dc.description.abstractObjectives: Doripenem is a new carbapenem recently introduced into Europe. The COMParative Activity of Carbapenem Testing (COMPACT) study compared the susceptibility of common Gram-negative bacilli causing serious infections in hospitalized patients with doripenem, imipenem and meropenem. Methods: Gram-negative isolates (4498 total: 2171 Pseudomonas species; 1910 Enterobacteriaceae; and 417 other Gram-negative bacilli) were collected from 80 centres in 16 countries in Europe, the Middle East and Africa during 2008-09. The MICs of doripenem, imipenem and meropenem were determined using Etest methodology and broth microdilution. Susceptibility was interpreted according to CLSI, EUCAST and FDA breakpoints. Results: The MIC(90)s of doripenem, imipenem and meropenem for all isolates were 8, >= 64 and 32 mg/L, respectively. Doripenem had the lowest MIC90 for Pseudomonas species at 16 mg/L, with imipenem and meropenem values of >= 64 mg/L. Enterobacteriaceae were highly susceptible to all three carbapenems, with MIC(90)s of doripenem, imipenem and meropenem of 0.06, 0.5 and 0.12 mg/L, respectively. Other Gram-negative isolates, predominantly Acinetobacter baumannii, were resistant to all three carbapenems (MIC90 >= 64 mg/L). Susceptibility to doripenem was observed in 14.9% of isolates resistant to imipenem and/or meropenem. Conclusions: Doripenem showed excellent activity against Gram-negative isolates; generally it was more active than imipenem and at least as good as meropenem. Against Pseudomonas species, doripenem was more active than both imipenem and meropenem, with doripenem susceptibility observed for some imipenem-and/or meropenem-resistant isolates.
dc.identifier.doi10.1093/jac/dkr056
dc.identifier.eissn1460-2091
dc.identifier.issn0305-7453
dc.identifier.pubmed21393160
dc.identifier.urihttps://hdl.handle.net/11424/244302
dc.identifier.wosWOS:000289584000019
dc.language.isoeng
dc.publisherOXFORD UNIV PRESS
dc.relation.ispartofJOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectdoripenem
dc.subjectGram-negative
dc.subjectimipenem
dc.subjectmeropenem
dc.subjectRESISTANCE SURVEILLANCE
dc.subjectPSEUDOMONAS-AERUGINOSA
dc.subjectSUSCEPTIBILITY
dc.subjectDORIPENEM
dc.subjectPROGRAM
dc.titleComparative activity of carbapenem testing: the COMPACT study
dc.typearticle
dspace.entity.typePublication
local.avesis.idbbec2951-bdcb-4f32-91ff-62a7ce73e808
local.import.packageSS16
local.indexed.atWOS
local.indexed.atSCOPUS
local.journal.numberofpages9
oaire.citation.endPage1078
oaire.citation.issue5
oaire.citation.startPage1070
oaire.citation.titleJOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
oaire.citation.volume66
relation.isAuthorOfPublication27f6afa3-0e46-45c9-a302-a6493c69bffb
relation.isAuthorOfPublication.latestForDiscovery27f6afa3-0e46-45c9-a302-a6493c69bffb

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
nordmann2011.pdf.pdf
Size:
220.13 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs